PRESTIGE-AF is the first of the larger trials in this scenario to report results. More data are needed to help guide ...

There is little information in the stroke literature on the adequacy of secondary prevention after IS and much of the findings from ASPIRE-S are therefore novel. The recent EUROASPIRE III stroke ...

The FDA said to stop all use of Philips' Tack Endovascular System, which is under class I recall for user difficulties in ...

Research by Sarasin and colleagues (2000) analyzed the cost effectiveness of antiplatelet regimens in secondary prevention of TIA ... the avoidance of additional stroke-related costs (Sarasin ...

Background Effective management of coexisting heart failure (HF), chronic kidney disease (CKD) and type 2 diabetes mellitus ...

Both reperfusion therapies and early thrombotic therapies for secondary prevention are currently controversial, with important variations in day-to-day practice. The aim of this Research Topic is to ...

Figure 1. Age-specific relations of systolic blood pressure with stroke mortality (A) in 61 cohorts (n=958 074; 70% of participants from Europe, 20% from North America or Australia, and 10% from Japan ...

Feinberg Award for Excellence in Clinical Stroke, delivered a compelling keynote at ISC 2025 titled "30 Years of Treatment for Acute Ischemic Cerebrovascular ... guided antiplatelet therapy in ...

These problems may be due to the stroke itself or a secondary cause, such as depression ... post-stroke seizures due to erratic electrical brain activity. Seizure prevention may be part of the ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

The discovery of a novel approach to promote cardiomyocyte proliferation offers new hope for the treatment of ischemic heart failure.